公开(公告)号：US09163017B2

公开(公告)日：2015-10-20

申请号：US14021435

申请日：2013-09-09

Applicant: ABBVIE INC.

Inventor： David A. Degoey ,  Pamela L. Donner ,  Warren M. Kati ,  Charles W. Hutchins ,  Mark A. Matulenko ,  Tammie K. Jinkerson ,  Ryan G. Keddy

IPC: C07D471/04

CPC classification number: C07D471/04

Abstract: Compounds effective in inhibiting replication of Hepatitis C virus (“HCV”) are described. This invention also relates to processes of making such compounds, compositions comprising such compounds, and methods of using such compounds to treat HCV infection.

Abstract translation: 描述了有效抑制丙型肝炎病毒（“HCV”）复制的化合物。 本发明还涉及制备这种化合物的方法，包含这些化合物的组合物，以及使用这些化合物治疗HCV感染的方法。

公开(公告)号：US20240158368A1

公开(公告)日：2024-05-16

申请号：US18379351

申请日：2023-10-12

Applicant: AbbVie Inc.

Inventor： David A. Degoey ,  Michael R. Schrimpf ,  David J. Hardee ,  Jacob Ludwig ,  Eric R. Miller ,  Timothy R. Hodges ,  Alberto Munoz ,  Sarah J. Perlmutter ,  Huan-Qiu X. Li ,  Alvin Jang ,  Elizabeth L. Noey ,  Gregory A. Gfesser ,  Edgars Jecs ,  Robert G. Schmidt ,  Justin D. Dietrich ,  Xenia B. Searle ,  Boguslaw P. Nocek ,  Andrew Bogdan

IPC: C07D401/12 ,  A61P31/14

CPC classification number: C07D401/12 ,  A61P31/14

Abstract: Pyrrolidine main protease inhibitors are described that are effective as antiviral compounds.

公开(公告)号：US20190119200A1

公开(公告)日：2019-04-25

申请号：US16091919

申请日：2017-04-06

Applicant: AbbVie Inc.

Inventor： Lawrence A. Black ,  William H. Bunnelle ,  Da Chen ,  Bruce Clapham ,  David A. Degoey ,  Xiangjun Deng ,  Liqiang Fu ,  Lisa A. Hazelwood ,  Linglong Kong ,  Qingyu Lang ,  Chih-Hung Lee ,  Mingfeng Li ,  Greta L. Lundgaard ,  Meena V. Patel ,  Ruihong Tao ,  Lin Zhang ,  Qingwei Zhang ,  Qiangang Zheng ,  Wei Zhu

IPC: C07C235/34 ,  C07D213/69 ,  C07D321/10 ,  C07D307/86 ,  C07D317/46 ,  C07D333/24 ,  C07C323/52 ,  C07F9/38 ,  C07C313/04 ,  C07D209/20 ,  C07C311/32 ,  C07D305/06 ,  C07D213/71 ,  C07C311/51 ,  C07D239/72 ,  C07D239/52 ,  C07D257/06 ,  C07D215/50 ,  C07D217/26 ,  C07D498/04 ,  C07D307/33

Abstract: Compounds of Formula (I) and pharmaceutically acceptable salts thereof, wherein G1, G2, G3, L1, L2, and L3 are as defined in the specification, are useful in treating conditions or disorders prevented by or ameliorated by the modulation of lysophosphatidic acid receptor 1. Methods for making the compounds are described. Also described are pharmaceutical compositions of compounds of formula (I), and methods for using such compounds and compositions.

公开(公告)号：US09249138B2

公开(公告)日：2016-02-02

申请号：US14017901

申请日：2013-09-04

Applicant: ABBVIE INC.

Inventor： David A. Degoey ,  Pamela L. Donner ,  Warren M. Kati ,  Charles W. Hutchins ,  Allan C. Krueger ,  John T. Randolph ,  Christopher E. Motter ,  Preethi Krishnan ,  Neeta C. Mistry ,  Tami J. Pilot-Matias ,  Sachin V. Patel ,  Xiaoyan Li ,  Todd N. Soltwedel ,  Lissa T. Nelson

IPC: C07D239/48 ,  C07D471/04

CPC classification number: C07D471/04 ,  C07D239/48

Abstract: Compounds effective in inhibiting replication of Hepatitis C virus (“HCV”) are described. This invention also relates to processes of making such compounds, compositions comprising such compounds, and methods of using such compounds to treat HCV infection.